Drug intelligence / Profile preview

BEIGESOME

Development stage: Preclinical
Lead developer: Exostemtech
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Subcutaneous, Intravenous

Overview

BEIGESOME is an exosome-based therapeutic candidate developed by Exostemtech for the treatment of metabolic disorders, including obesity, diabetes, and fatty liver disease. The therapy utilizes exosomes to induce the browning of white adipose tissue (WAT), a process that converts energy-storing white fat into energy-burning beige fat. By promoting thermogenesis and enhancing metabolic activity, BEIGESOME aims to reduce body weight, improve insulin sensitivity, and alleviate hepatic steatosis. It is currently in the preclinical stage of development.

Brand names: BEIGESOME

Beyond the preview

Go deeper on BEIGESOME.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BEIGESOME.

Explore the full profile